Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...
Clinical Trials Arena4d
ACC 25: semaglutide reduces total cardiovascular events in latest SELECT results
The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...
JD Supra11d
FDA Update: Current Guidelines for Semaglutide and Tirzepatide Compounding
Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Verywell Health on MSN3d
Contrave vs. Wegovy: How Do They Compare for Weight Loss?
Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...
Medscape4d
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
MedPage Today7d
STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery Disease
In the randomized STRIDE trial, a year of semaglutide (Ozempic, Wegovy) injections increased the walking ability of people with type 2 diabetes (T2D) and lower limb PAD by 21%, a significant ...
NBC New York4d
Hims & Hers shares rise as company adds new weight-loss medications to platform
The U.S. Food and Drug Administration announced in February that the shortage of semaglutide injections products had been resolved. That meant Hims & Hers had to largely stop offering the ...